

Neuronetics, Inc. Supplemental Financial and Operating Information

For the period ended September 30, 2023

Revenue (\$ thousands)	2021				2022				2023			2021	2022
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	FY	FY
Total U.S. NeuroStar Advanced Therapy System Revenues	\$1,755	\$2,577	\$2,612	\$2,815	\$3,642	\$4,382	\$3,934	\$4,616	\$3,850	\$4,489	\$3,597	\$9,760	\$16,575
<i>YoY Change</i>	-32%	10%	3%	-22%	108%	70%	51%	64%	6%	2%	-9%	-12%	70%
Total U.S. Treatment Sessions Revenues	\$9,629	\$10,801	\$10,259	\$11,245	\$9,469	\$11,295	\$11,864	\$12,450	\$10,643	\$12,314	\$13,060	\$41,933	\$45,077
<i>YoY Change</i>	18%	65%	13%	2%	-2%	5%	16%	11%	12%	9%	10%	20%	7%
Total U.S. Other Revenues	\$419	\$431	\$409	\$496	\$406	\$455	\$446	\$447	\$471	\$486	\$554	\$1,754	\$1,754
<i>YoY Change</i>	7%	13%	1%	25%	-3%	6%	9%	-10%	16%	7%	24%	12%	0%
Total U.S. Revenues	\$11,802	\$13,809	\$13,280	\$14,556	\$13,517	\$16,132	\$16,244	\$17,513	\$14,964	\$17,289	\$17,211	\$53,447	\$63,406
<i>YoY Change</i>	6%	49%	10%	-3%	15%	17%	22%	20%	11%	7%	6%	12%	19%
Total International Revenues	\$486	\$394	\$519	\$466	\$664	\$198	\$253	\$686	\$576	\$321	\$673	\$1,865	\$1,800
<i>YoY Change</i>	63%	-17%	24%	-13%	36%	-50%	-51%	47%	-13%	62%	165%	8%	-3%
Total Revenues	\$12,288	\$14,203	\$13,799	\$15,022	\$14,181	\$16,329	\$16,498	\$18,199	\$15,540	\$17,610	\$17,884	\$55,312	\$65,206
<i>YoY Change</i>	7%	46%	11%	-4%	15%	15%	20%	21%	10%	8%	8%	12%	18%
U.S. Operating and Financial Metrics	2021				2022				2023			2021	2022
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	FY	FY
Total NeuroStar Systems	23	36	40	48	46	59	50	58	49	54	43	147	213
<i>YoY Change</i>	-39%	3%	3%	-11%	100%	64%	25%	21%	7%	-8%	-14%	-11%	45%
Average Revenue Per Active Site (\$) (1)	\$10,512	\$12,001	\$11,163	\$12,183	\$9,874	\$11,280	\$11,364	\$11,517	\$9,667	\$11,391	\$11,916		
<i>YoY Change</i>	12%	62%	9%	0.4%	-6%	-6%	2%	-5%	-2%	1%	5%		

(1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)